{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:01:53Z","timestamp":1794031313345,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Recently developed once-weekly basal insulin analogs, including insulin icodec and insulin efsitora alpha (efsitora), aim to improve treatment adherence and patient convenience compared with daily basal insulin. This systematic review and meta-analysis evaluated the efficacy and safety of once-weekly basal insulin analogs compared with daily basal insulin analogs in adults with type 2 diabetes mellitus (T2DM) and included 14 randomized controlled trials (RCTs), comprising 8,487 subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Evidence supports that once-weekly basal insulin analogs achieve comparable glycemic control to daily basal insulin analogs in adults with T2DM, offering greater reductions in HbA1c and improvements in time in range, with a safety profile similar to that of daily insulin regimens. In our analysis, once-weekly basal insulin resulted in a greater reduction in HbA1c compared with daily basal insulin (mean difference [MD] -0.09%, 95% CI -0.15 to -0.03), greater improvements in time in range (TIR) (MD 1.86%, 95% CI 0.73 to 2.98) and higher odds of attaining an HbA1c\u2009&lt;\u20097.0% (OR 1.32, 95% CI 1.07 to 1.63, I2 64.9%). Rates of level 2 or 3 hypoglycemia did not differ significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Once-weekly basal insulin provides glycemic control comparable to daily basal insulin, with modest improvements in glycemic outcomes and similar hypoglycemia risk. Its primary advantage lies in treatment simplification and reduced injection burden, supporting its role as a convenient alternative to daily basal insulin in adults with T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11892-026-01628-3","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:48:03Z","timestamp":1781232483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2348-7312","authenticated-orcid":false,"given":"Dimitrios","family":"Raptis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-9434","authenticated-orcid":false,"given":"Sotirios","family":"Chiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6552-6738","authenticated-orcid":false,"given":"Theodoros","family":"Papamichalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-3835","authenticated-orcid":false,"given":"Eleni","family":"Bekiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-4072","authenticated-orcid":false,"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-0574","authenticated-orcid":false,"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025. Diabetes Care. 2024;48:S181\u2013206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMoa2303208","volume":"389","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Bain SC, Gowda A, J\u00f3dar E, Liang B, Lingvay I, et al. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med. 2023;389:297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2303208.","journal-title":"N Engl J Med"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3390\/jcm13072113","volume":"13","author":"Y Ingrasciotta","year":"2024","unstructured":"Ingrasciotta Y, Vitturi G, Trifir\u00f2 G. Pharmacological and Benefit-Risk Profile of Once-Weekly Basal Insulin Administration (Icodec): Addressing Patients\u2019 Unmet Needs and Exploring Future Applications. J Clin Med. 2024;13:2113. https:\/\/doi.org\/10.3390\/jcm13072113.","journal-title":"J Clin Med"},{"key":"1628_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/dom.14871","volume":"25","author":"A Philis-Tsimikas","year":"2023","unstructured":"Philis-Tsimikas A, Bajaj HS, Begtrup K, Cailleteau R, Gowda A, Lingvay I, et al. Rationale and design of the phase 3a development programme (ONWARDS 1\u20136 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab Engl. 2023;25:331\u201341. https:\/\/doi.org\/10.1111\/dom.14871.","journal-title":"Diabetes Obes Metab Engl"},{"key":"1628_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403953","author":"C Wysham","year":"2024","unstructured":"Wysham C, Bajaj HS, Del Prato S, Franco DR, Kiyosue A, Dahl D, et al. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2403953.","journal-title":"N Engl J Med"},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/endrev\/bnad037","volume":"45","author":"J Rosenstock","year":"2024","unstructured":"Rosenstock J, Juneja R, Beals JM, Moyers JS, Ilag L, McCrimmon RJ. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocr Rev United States. 2024;45:379\u2013413. https:\/\/doi.org\/10.1210\/endrev\/bnad037.","journal-title":"Endocr Rev United States"},{"key":"1628_CR7","doi-asserted-by":"publisher","unstructured":"Blair HA. Insulin Icodec: First Approval. BioDrugs Clin Immunother Biopharm Gene Ther. 2024;38:717\u201324. https:\/\/doi.org\/10.1007\/s40259-024-00670-5","DOI":"10.1007\/s40259-024-00670-5"},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100.","journal-title":"PLoS Med"},{"key":"1628_CR9","unstructured":"Cochrane Handbook for Systematic Reviews. of Interventions | Cochrane [Internet]. [cited 2026 Feb 22]. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook. Accessed 22 Feb 2026."},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.2337\/dc26-S006","volume":"49","author":"6","year":"2025","unstructured":"6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes\u20142026. Diabetes Care. 2025;49:S132\u201349. https:\/\/doi.org\/10.2337\/dc26-S006.","journal-title":"Diabetes Care"},{"key":"1628_CR12","unstructured":"Risk of bias tools -. RoB 2 tool [Internet]. [cited 2025 June 13]. https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool. Accessed 13 June 2025."},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/09622802241231496","volume":"33","author":"Y Wang","year":"2024","unstructured":"Wang Y, DelRocco N, Lin L. Comparisons of various estimates of the I2 statistic for quantifying between-study heterogeneity in meta-analysis. Stat Methods Med Res. 2024;33:745\u201364. https:\/\/doi.org\/10.1177\/09622802241231496.","journal-title":"Stat Methods Med Res"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1161\/CIR.0000000000000523","volume":"136","author":"G Rao","year":"2017","unstructured":"Rao G, Lopez-Jimenez F, Boyd J, D\u2019Amico F, Durant NH, Hlatky MA, et al. Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association. Circulation Am Heart Association. 2017;136:e172\u201394. https:\/\/doi.org\/10.1161\/CIR.0000000000000523.","journal-title":"Circulation Am Heart Association"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-8587(22)00388-6","volume":"11","author":"J Frias","year":"2023","unstructured":"Frias J, Chien J, Zhang Q, Chigutsa E, Landschulz W, Syring K, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol. 2023;11:158\u201368. https:\/\/doi.org\/10.1016\/S2213-8587(22)00388-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1628_CR16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2337\/dc22-2396","volume":"46","author":"JM Bue-Valleskey","year":"2023","unstructured":"Bue-Valleskey JM, Kazda CM, Ma C, Chien J, Zhang Q, Chigutsa E, et al. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care. 2023;46:1060\u20137. https:\/\/doi.org\/10.2337\/dc22-2396.","journal-title":"Diabetes Care"},{"key":"1628_CR17","doi-asserted-by":"publisher","unstructured":"R\u00fccker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta\u2010analysis. [cited 2026 Apr 7]; https:\/\/doi.org\/10.1002\/jrsm.1259","DOI":"10.1002\/jrsm.1259"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"1628_CR19","unstructured":"Chapter 13. Assessing risk of bias due to missing evidence in a meta-analysis | Cochrane [Internet]. [cited 2026 Feb 22]. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-13. Accessed 22 Feb 2026."},{"key":"1628_CR20","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002.","journal-title":"BMJ"},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","volume":"383","author":"J Rosenstock","year":"2020","unstructured":"Rosenstock J, Bajaj HS, Jane\u017e A, Silver R, Begtrup K, Hansen MV, et al. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. 2020;383:2107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2022474.","journal-title":"N Engl J Med"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.2337\/dc20-2877","volume":"44","author":"HS Bajaj","year":"2021","unstructured":"Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes Care. 2021;44:1586\u201394. https:\/\/doi.org\/10.2337\/dc20-2877.","journal-title":"Diabetes Care"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/dc20-2878","volume":"44","author":"I Lingvay","year":"2021","unstructured":"Lingvay I, Buse JB, Franek E, Hansen MV, Koefoed MM, Mathieu C, et al. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes Care. 2021;44:1595\u2013603. https:\/\/doi.org\/10.2337\/dc20-2878.","journal-title":"Diabetes Care"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-8587(23)00093-1","volume":"11","author":"A Philis-Tsimikas","year":"2023","unstructured":"Philis-Tsimikas A, Asong M, Franek E, Jia T, Rosenstock J, Stachlewska K, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol Engl. 2023;11:414\u201325. https:\/\/doi.org\/10.1016\/S2213-8587(23)00093-1.","journal-title":"Lancet Diabetes Endocrinol Engl"},{"key":"1628_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.2023.11313","volume":"330","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Asong M, Desouza C, Gourdy P, Kar S, Vianna A, et al. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. JAMA. 2023;330:228\u201337. https:\/\/doi.org\/10.1001\/jama.2023.11313.","journal-title":"JAMA"},{"key":"1628_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(23)00520-2","volume":"401","author":"C Mathieu","year":"2023","unstructured":"Mathieu C, \u00c1sbj\u00f6rnsd\u00f3ttir B, Bajaj HS, Lane W, Matos ALSA, Murthy S, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet Lond Engl Engl. 2023;401:1929\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(23)00520-2.","journal-title":"Lancet Lond Engl Engl"},{"key":"1628_CR27","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.7326\/M23-1288","volume":"176","author":"HS Bajaj","year":"2023","unstructured":"Bajaj HS, Aberle J, Davies M, Donatsky AM, Frederiksen M, Yavuz DG, et al. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5): A Randomized Trial. Ann Intern Med United States. 2023;176:1476\u201385. https:\/\/doi.org\/10.7326\/M23-1288.","journal-title":"Ann Intern Med United States"},{"key":"1628_CR28","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(25)01044-X","volume":"405","author":"A Philis-Tsimikas","year":"2025","unstructured":"Philis-Tsimikas A, Bergenstal RM, Bailey TS, Jinnouchi H, Thrasher JR, Ilag L, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet Lond Engl. 2025;405:2279\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(25)01044-X.","journal-title":"Lancet Lond Engl"},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/S0140-6736(25)01069-4","volume":"405","author":"T Blevins","year":"2025","unstructured":"Blevins T, Dahl D, P\u00e9rez Manghi FC, Murthy S, Ortiz Carrasquillo R, Li X, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet Lond Engl. 2025;405:2290\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(25)01069-4.","journal-title":"Lancet Lond Engl"},{"key":"1628_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2502796","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Bailey T, Connery L, Miller E, Desouza C, Wang Q, et al. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. N Engl J Med. 2025;393:325\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2502796.","journal-title":"N Engl J Med"},{"key":"1628_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-8587(23)00093-1","volume":"11","author":"A Philis-Tsimikas","year":"2023","unstructured":"Philis-Tsimikas A, Asong M, Franek E, Jia T, Rosenstock J, Stachlewska K, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414\u201325. https:\/\/doi.org\/10.1016\/S2213-8587(23)00093-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1628_CR32","doi-asserted-by":"publisher","unstructured":"Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. London, England; 2024;404:145\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(24)00537-3","DOI":"10.1016\/S0140-6736(24)00537-3"},{"key":"1628_CR33","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.jacc.2016.08.070","volume":"68","author":"MO Gore","year":"2016","unstructured":"Gore MO, McGuire DK. A Test in Context: Hemoglobin A1c and Cardiovascular Disease. J Am Coll Cardiol. 2016;68:2479\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2016.08.070.","journal-title":"J Am Coll Cardiol"},{"key":"1628_CR34","doi-asserted-by":"publisher","first-page":"102877","DOI":"10.1016\/j.dsx.2023.102877","volume":"17","author":"D Dutta","year":"2023","unstructured":"Dutta D, Nagendra L, Bhat S, Mohindra R, Surana V, Misra A. Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials. Diabetes Metab Syndr Neth. 2023;17:102877. https:\/\/doi.org\/10.1016\/j.dsx.2023.102877.","journal-title":"Diabetes Metab Syndr Neth"},{"key":"1628_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15259","author":"P Karakasis","year":"2023","unstructured":"Karakasis P, Patoulias D, Pamporis K, Popovic DS, Stachteas P, Bougioukas KI, et al. Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2023. https:\/\/doi.org\/10.1111\/dom.15259.","journal-title":"Diabetes Obes Metab"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/dom.15408","volume":"26","author":"S Shetty","year":"2024","unstructured":"Shetty S, Suvarna R. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials. Diabetes Obes Metab. 2024;26:1069\u201381. https:\/\/doi.org\/10.1111\/dom.15408.","journal-title":"Diabetes Obes Metab"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.eprac.2023.11.004","volume":"30","author":"P Mukhopadhyay","year":"2024","unstructured":"Mukhopadhyay P, Chatterjee P, Pandit K, Sanyal D, Ghosh S. Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2024;30:128\u201334. https:\/\/doi.org\/10.1016\/j.eprac.2023.11.004.","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"1628_CR38","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1111\/dom.15726","volume":"26","author":"HS Bajaj","year":"2024","unstructured":"Bajaj HS, \u00c1sbj\u00f6rnsd\u00f3ttir B, Bari TJ, Begtrup K, Vilsb\u00f8ll T, Rosenstock J. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1\u20135 trials. Diabetes Obes Metab. 2024;26:3810\u201320. https:\/\/doi.org\/10.1111\/dom.15726.","journal-title":"Diabetes Obes Metab"},{"key":"1628_CR39","doi-asserted-by":"publisher","first-page":"e36308","DOI":"10.1097\/MD.0000000000036308","volume":"102","author":"X Wang","year":"2023","unstructured":"Wang X, Xiao W, Liang Z, Li S, Tang Q. Efficacy and safety of once-weekly basal insulin versus once-daily basal insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Med (Baltim). 2023;102:e36308. https:\/\/doi.org\/10.1097\/MD.0000000000036308.","journal-title":"Med (Baltim)"},{"key":"1628_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0712","volume":"86","author":"R Ahmed","year":"2025","unstructured":"Ahmed R, Shafiq A, Ahmed M, Once-Weekly Insulin. A Breakthrough in Diabetes Management or an Unresolved Challenge? Br J Hosp Med Lond Engl 2005. 2025;86:1\u20136. https:\/\/doi.org\/10.12968\/hmed.2024.0712.","journal-title":"Br J Hosp Med Lond Engl 2005"},{"key":"1628_CR41","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034.","journal-title":"Diabetes Care"},{"key":"1628_CR42","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","volume":"384","author":"C Eng","year":"2014","unstructured":"Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet Lond Engl. 2014;384:2228\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(14)61335-0.","journal-title":"Lancet Lond Engl"},{"key":"1628_CR43","unstructured":"A 40-week study comparing the efficacy and safety of once weekly. IcoSema and Daily Insulin Glargine 100 Units\/mL in Participants With Type 2 Diabetes Inadequately Controlled on Oral Anti Diabetic Drugs COMBINE 4 [Internet]. 2024 [cited 2024 Feb 15]. https:\/\/clinicaltrials.gov\/study\/NCT06269107. Accessed 15 Feb 2024."},{"key":"1628_CR44","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S2213-8587(25)00052-X","volume":"13","author":"LK Billings","year":"2025","unstructured":"Billings LK, Andreozzi F, Frederiksen M, Gourdy P, Gowda A, Ji L, et al. Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025;13:556\u201367. https:\/\/doi.org\/10.1016\/S2213-8587(25)00052-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1628_CR45","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S2213-8587(25)00096-8","volume":"13","author":"C Mathieu","year":"2025","unstructured":"Mathieu C, Giorgino F, Kim SG, Larsen JH, Philis-Tsimikas A, Ramachandran A, et al. Once\u2013weekly IcoSema versus once\u2013weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open\u2013label, multicentre, treat\u2013to\u2013target, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025;13:568\u201379. https:\/\/doi.org\/10.1016\/S2213-8587(25)00096-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1628_CR46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00125-024-06348-5","volume":"68","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Benamar M, Chen L, Fu A, J\u00f3dar E, Nishida T, et al. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia. 2025;68:739\u201351. https:\/\/doi.org\/10.1007\/s00125-024-06348-5.","journal-title":"Diabetologia"},{"key":"1628_CR47","doi-asserted-by":"publisher","first-page":"e0130619","DOI":"10.1371\/journal.pone.0130619","volume":"10","author":"RW Scherer","year":"2015","unstructured":"Scherer RW, Huynh L, Ervin A-M, Dickersin K. Using ClinicalTrials.gov to supplement information in ophthalmology conference abstracts about trial outcomes: a comparison study. PloS One. 2015;10:e0130619. https:\/\/doi.org\/10.1371\/journal.pone.0130619","journal-title":"PloS One"},{"key":"1628_CR48","doi-asserted-by":"publisher","unstructured":"Saric L, Vucic K, Dragicevic K, Vrdoljak M, Jakus D, Vuka I et al. Comparison of conference abstracts and full-text publications of randomized controlled trials presented at four consecutive World Congresses of Pain: Reporting quality and agreement of results. Eur J Pain. London, England; 2019;23:107\u201316. https:\/\/doi.org\/10.1002\/ejp.1289","DOI":"10.1002\/ejp.1289"},{"key":"1628_CR49","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13643-019-1188-0","volume":"8","author":"RW Scherer","year":"2019","unstructured":"Scherer RW, Saldanha IJ. How should systematic reviewers handle conference abstracts? A view from the trenches. Syst Rev. 2019;8:264. https:\/\/doi.org\/10.1186\/s13643-019-1188-0.","journal-title":"Syst Rev"},{"key":"1628_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13643-022-02048-6","volume":"11","author":"S Hackenbroich","year":"2022","unstructured":"Hackenbroich S, Kranke P, Meybohm P, Weibel S. Include or not to include conference abstracts in systematic reviews? Lessons learned from a large Cochrane network meta-analysis including 585 trials. Syst Rev. 2022;11:178. https:\/\/doi.org\/10.1186\/s13643-022-02048-6.","journal-title":"Syst Rev"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-026-01628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-026-01628-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-026-01628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:48:07Z","timestamp":1781232487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-026-01628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s11892-026-01628-3","relation":{},"ISSN":["1539-0829"],"issn-type":[{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eleni Bekiari has received research support from Novo Nordisk, support to attend meeting and speaker\u2019s fees from Menarini, and speaker\u2019s fees for Sanofi. Apostolos Tsapas is section editor of Current Diabetes Reports.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"16"}}